Mosaic Financial Group LLC Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Mosaic Financial Group LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 180.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,856 shares of the company’s stock after acquiring an additional 3,126 shares during the quarter. Mosaic Financial Group LLC’s holdings in Novo Nordisk A/S were worth $418,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GQG Partners LLC grew its position in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the period. Loomis Sayles & Co. L P grew its holdings in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the period. Folketrygdfondet increased its stake in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after purchasing an additional 40,313 shares in the last quarter. Sustainable Growth Advisers LP lifted its holdings in shares of Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $404,910,000. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

NVO has been the subject of a number of analyst reports. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 21st. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $69.58 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a 50 day moving average price of $82.15 and a 200-day moving average price of $98.17. Novo Nordisk A/S has a 52 week low of $66.88 and a 52 week high of $148.15. The firm has a market capitalization of $312.24 billion, a PE ratio of 21.15, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.